H-FABP, which is a low-weight cytoplasmic protein (15kDa), demonstrated high sensitivity.
Study from the University of Manchester, UK, suggested that using a combination hsTnT, H-FABP and ECG on admission, could act as a highly accurate rule-out test for AMI.
Two recent landmark studies from a group based at Leeds General Infirmary, UK, showed that H-FABP offers independent and additive prognostic value across the full spectrum of ACS patients, and is a significant predictor of mortality in both Troponin positive and negative patients.
The Troponin negative patients are of particular importance, as this group are usually stratified as low-risk and frequently may be discharged from hospital.